M Chen1, J Li, Y Zhang. 1. Cancer Center, Sun Yet-sen University of Medical Sciences, Guangzhou 510060, China.
Abstract
OBJECTIVE: To report the method and result of high dose iodized oil chemoembolization for the treatment of large hepatocellular carcinoma. METHODS: From 1993 to 1998, 163 patients with unresectable hepatocellular carcinoma were treated by transarterial chemoembolization (TACE) with more than 20 ml lipiodol. RESULTS: TACE with high dose lipiodol was well tolerated by the treated patients. In patients whose liver function was of Child A stage, or in patients whose residual indocyanine green level 15 min after injection was less than 20%, the frequency of post-treatment hepatic insufficiency was not significantly different from that of patients treated with routine dose of lipiodol. On CT scan at 4 wk after TACE, more lipiodol was located in the liver. The 1-, 2-,3-year survival rate of patients in Child A stage was 79.8%, 50.3%, and 38.5%, respectively, as compared to 57.5%, 24.8% and 8.37%, respectively in patients treated with routine dose of lipiodol (P = 0.0136). CONCLUSION: High dose lipiodol TACE for the treatment of large hepatocellular carcinoma is practically acceptable with better therapeutic effect but its use should be limited to those patients with compensated liver function.
OBJECTIVE: To report the method and result of high dose iodized oil chemoembolization for the treatment of large hepatocellular carcinoma. METHODS: From 1993 to 1998, 163 patients with unresectable hepatocellular carcinoma were treated by transarterial chemoembolization (TACE) with more than 20 ml lipiodol. RESULTS:TACE with high dose lipiodol was well tolerated by the treated patients. In patients whose liver function was of Child A stage, or in patients whose residual indocyanine green level 15 min after injection was less than 20%, the frequency of post-treatment hepatic insufficiency was not significantly different from that of patients treated with routine dose of lipiodol. On CT scan at 4 wk after TACE, more lipiodol was located in the liver. The 1-, 2-,3-year survival rate of patients in Child A stage was 79.8%, 50.3%, and 38.5%, respectively, as compared to 57.5%, 24.8% and 8.37%, respectively in patients treated with routine dose of lipiodol (P = 0.0136). CONCLUSION: High dose lipiodolTACE for the treatment of large hepatocellular carcinoma is practically acceptable with better therapeutic effect but its use should be limited to those patients with compensated liver function.